Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02176213 · ClinicalTrials.gov registry record · Phase 2
Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma
A Phase 2 study, sponsored by Ajai Chari.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT02176213: Completed Phase 2 study, sponsored by Ajai Chari.
NCT02176213 is a Phase 2 study that has completed, run by Ajai Chari. The registered enrollment target is 35 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02176213, a Phase 2 study, has completed, sponsored by Ajai Chari.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
This study is being done to learn more about the drug, pomalidomide and to gather data on its safety and side effects when used in combination with commercially available cyclophosphamide and dexamethasone. This combination is considered experimental and has not been approved by the FDA. Pomalidomide is a third generation immunomodulatory (IMiDs) agent, which is a more potent version of thalidomide and lenalidomide drugs that have been approved by the United States Food and Drug Administration \[FDA\] for the treatment of MM. In February 2013, pomalidomide was also approved by the FDA for patients with MM who have had more than 2 types of therapy. Pomalidomide is taken orally as capsules, and cyclophosphamide and dexamethasone are also taken orally as tablets in this study. Cyclophosphamide and dexamethasone are commercially available and are often used in combination with other drugs to treat Multiple Myeloma. Preliminary data from both the laboratory and patient studies suggest that this combination of drugs is more effective than pomalidomide and dexamethasone alone. However, the regimen being used in this study, which consists of daily cyclophosphamide, also permits support of low blood counts with either injections or transfusions as needed.
Interventions
- DRUG Cyclophosphamide
- DRUG Dexamethasone
- DRUG Pomalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2014-06 |
| Est. Completion | 2019-05-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02176213
The ClinicalTrials.gov registry entry for NCT02176213 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ajai Chari, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT02176213 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02176213 about?
NCT02176213 is a clinical study titled "Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma". This study is being done to learn more about the drug, pomalidomide and to gather data on its safety and side effects when used in combination with commercially available cyclophosphamide and dexamethasone. This combination is considered experimental and has not been approved by the FDA. Pomalidomi...
What is the current status of trial NCT02176213?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2014-06. Estimated completion is 2019-05-07.
What interventions are being tested in trial NCT02176213?
The interventions under investigation include: Cyclophosphamide (DRUG), Dexamethasone (DRUG), Pomalidomide (DRUG).
Who is sponsoring clinical trial NCT02176213?
This trial is sponsored by Ajai Chari, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.